Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round
MBX is applying peptide optimization tech from an Indiana University lab to rare endocrine disorders
Kent Hawryluk and Richard DiMarchi are following up on the first two companies they formed together, diabetes-focused Marcadia and MB2, with rare endocrine diseases play MBX Biosciences.
Frazier, which led Marcadia Biotech Inc.’s series A round, also led MBX Biosciences Inc.’s $34.6 million series A. Other participants in the Indiana-based company’s financing, which includes
